DE69528058D1 - Bmp-9 zusammensetzungen - Google Patents

Bmp-9 zusammensetzungen

Info

Publication number
DE69528058D1
DE69528058D1 DE69528058T DE69528058T DE69528058D1 DE 69528058 D1 DE69528058 D1 DE 69528058D1 DE 69528058 T DE69528058 T DE 69528058T DE 69528058 T DE69528058 T DE 69528058T DE 69528058 D1 DE69528058 D1 DE 69528058D1
Authority
DE
Germany
Prior art keywords
bmp
compositions
proteins
bone
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69528058T
Other languages
English (en)
Other versions
DE69528058T2 (de
Inventor
A Rosen
M Wozney
J Celeste
R Thies
J Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of DE69528058D1 publication Critical patent/DE69528058D1/de
Application granted granted Critical
Publication of DE69528058T2 publication Critical patent/DE69528058T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
DE69528058T 1994-06-06 1995-06-05 Bmp-9 zusammensetzungen Expired - Fee Related DE69528058T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/254,353 US6287816B1 (en) 1991-06-25 1994-06-06 BMP-9 compositions
PCT/US1995/007084 WO1995033830A1 (en) 1994-06-06 1995-06-05 Bmp-9 compositions

Publications (2)

Publication Number Publication Date
DE69528058D1 true DE69528058D1 (de) 2002-10-10
DE69528058T2 DE69528058T2 (de) 2003-05-28

Family

ID=22963968

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528058T Expired - Fee Related DE69528058T2 (de) 1994-06-06 1995-06-05 Bmp-9 zusammensetzungen

Country Status (8)

Country Link
US (2) US6287816B1 (de)
EP (2) EP1230930A3 (de)
JP (1) JP3706133B2 (de)
KR (1) KR100255417B1 (de)
AT (1) ATE223486T1 (de)
AU (1) AU709869B2 (de)
DE (1) DE69528058T2 (de)
WO (1) WO1995033830A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5656593A (en) * 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
DE69233022T2 (de) * 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US20080070842A1 (en) * 1991-11-04 2008-03-20 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998034655A1 (en) 1997-02-07 1998-08-13 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US6034062A (en) * 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
EP0980252B1 (de) 1997-05-05 2004-10-06 Curis, Inc. Therapien zur behandlung von akutem nierenversagen
CA2291514C (en) 1997-05-30 2011-07-12 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
ES2226467T5 (es) * 1998-11-13 2009-08-27 Stryker Corporation Aliviamiento de los sintomas del cancer de prostata.
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
JP2003508493A (ja) * 1999-09-08 2003-03-04 ジェネティックス・インスチチュート・インコーポレーテッド Ｂｍｐ−９組成物およびコリン作動性ニューロンの分化誘導方法
US6723334B1 (en) * 2000-03-01 2004-04-20 Iowa State University Research Foundation, Inc. Biologically compatible bone cements and orthopedic methods
WO2002077006A1 (en) * 2001-03-23 2002-10-03 Human Genome Sciences, Inc. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
US20020114795A1 (en) 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
WO2002067978A1 (en) * 2001-02-23 2002-09-06 Wyeth Chondrogenic potential of human bone marrow-derived cd105+ cells by bmp
DE60226321T2 (de) * 2001-06-01 2009-07-09 Wyeth Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
AU2003221582A1 (en) 2002-05-03 2003-11-17 Millenium Biologix Inc. Connective tissue stimulating peptides
TWI282283B (en) * 2002-05-17 2007-06-11 Wyeth Corp Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
JP2007524376A (ja) * 2003-03-27 2007-08-30 チルドレンズ ホスピタル メディカル センター 軟骨形成を誘導するｆｇｆ−１８タンパク質、標的タンパク質、およびそれぞれをコードするヌクレオチド配列の使用
ES2282904T3 (es) 2003-09-12 2007-10-16 Wyeth Barras solidas de fosfato calcico inyectables para el suministro de proteinas osteogenicas.
PT1737734E (pt) 2004-03-10 2010-11-11 Scil Technology Gmbh Implantes revestidos, seu fabrico e utilização
EP2298335B1 (de) 2004-05-25 2014-09-03 Stryker Corporation Verwendung von OP-1 zur Behandlung von Knorpeldefekten
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US20060166251A1 (en) * 2005-01-26 2006-07-27 Archambault Joanne M Use of sFRPs as markers of BMP activity
AU2006230434A1 (en) * 2005-03-30 2006-10-05 Wyeth Methods for stimulating hair growth by administering BMPs
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CA2652549A1 (en) 2006-05-17 2007-12-13 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5452230B2 (ja) 2006-12-21 2014-03-26 ストライカー コーポレイション 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
BRPI0806861A2 (pt) 2007-02-01 2014-08-05 Acceleron Pharma Inc Antagonistas de ativina-actriia e usos para tratar ou prevenir câncer de mama
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
BRPI0807506B1 (pt) 2007-02-09 2022-02-15 Acceleron Pharma, Inc Uso de uma proteína de fusão actriia-fc para a fabricação de um medicamento para tratar ou previnir mieloma múltiplo
DE102007006843A1 (de) 2007-02-12 2008-08-14 Bioregeneration Gmbh Verfahren und Stützstruktur zum Kultivieren lebender Zellen
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
EP2268302B1 (de) 2008-02-13 2014-04-09 Keith Hruska Bmp-7 zur behandlung von neointimaler hyperplasie
EP2276458A1 (de) 2008-04-14 2011-01-26 Advanced Technologies and Regenerative Medicine, LLC Flüssige gepufferte gdf-5-formulierungen
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI472336B (zh) 2008-08-14 2015-02-11 Acceleron Pharma Inc 使用ｇｄｆ阱以增加紅血球水平
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
JP5819733B2 (ja) 2009-02-12 2015-11-24 ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与
EP2396026A2 (de) 2009-02-12 2011-12-21 Stryker Corporation Zusammensetzungen und verfahren für die minimal invasive systemische abgabe von proteinen einschliesslich mitglieder der tgf-superfamilie
WO2010110974A1 (en) 2009-03-24 2010-09-30 Stryker Corporation Methods and compositions for tissue engineering
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
KR20190090049A (ko) 2009-06-12 2019-07-31 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
US20110224138A1 (en) 2009-09-09 2011-09-15 Julie Krop Methods for treating pain induced by injuries and diseases of an articular joint
BR112012005225B8 (pt) * 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
WO2011035094A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
CA2779472C (en) * 2009-11-03 2021-03-16 Acceleron Pharma Inc. The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease
CA2781152A1 (en) * 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2013514811A (ja) 2009-12-22 2013-05-02 ストライカー コーポレイション 免疫原性が抑制されたｂｍｐ−７変異体
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
SG187589A1 (en) 2010-08-20 2013-03-28 Wyeth Llc Designer osteogenic proteins
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
CA2817584C (en) 2010-11-15 2018-01-02 Zimmer Orthobiologics, Inc. Bone void fillers
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CA2918486C (en) * 2012-07-20 2020-12-08 The Regents Of The University Of California Methods for producing cartilage and bone
US9833481B2 (en) * 2012-09-01 2017-12-05 Ken Muneoka Method for articular cartilage and joint formation
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
US20160257728A1 (en) * 2013-10-17 2016-09-08 joint Center for Biosciences Bioactive recombinant bmp-9 protein, mb109, expressed and isolated from bacteria
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3227675B1 (de) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii-antagonisten und verwendungen davon zur behandlung von myelodysplastischem syndrom
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455256A (en) 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US4789732A (en) 1980-08-04 1988-12-06 Regents Of The University Of California Bone morphogenetic protein composition
US4619989A (en) 1981-05-05 1986-10-28 The Regents Of The University Of Cal. Bone morphogenetic protein composition
US4294753A (en) 1980-08-04 1981-10-13 The Regents Of The University Of California Bone morphogenetic protein process
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4434094A (en) 1983-04-12 1984-02-28 Collagen Corporation Partially purified osteogenic factor and process for preparing same from demineralized bone
US4795804A (en) 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
US4804744A (en) 1984-01-04 1989-02-14 International Genetic Engineering, Inc. Osteogenic factors
US4608199A (en) 1984-03-20 1986-08-26 Arnold Caplan Bone protein purification process
US4843063A (en) 1984-07-16 1989-06-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4627982A (en) 1984-07-16 1986-12-09 Collagen Corporation Partially purified bone-inducing factor
ATE128715T1 (de) 1984-07-16 1995-10-15 Celtrix Pharma Polypeptide induzierende faktoren in knochen und knorpel.
US4563350A (en) 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US4886747A (en) 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4681763A (en) 1985-06-11 1987-07-21 University Of Medicine And Dentistry Of New Jersey Composition for stimulating bone growth
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4737578A (en) 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
EP0336760A3 (de) 1988-04-06 1991-03-13 Celtrix Pharmaceuticals, Inc. Knochenwachstum induzierendes Protein
WO1989009787A2 (en) 1988-04-08 1989-10-19 Creative Biomolecules, Inc. Osteogenic devices
US4968590A (en) 1988-04-08 1990-11-06 Stryker Corporation Osteogenic proteins and polypeptides
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
FR2636063B1 (fr) * 1988-09-05 1993-04-30 Centre Nat Rech Scient Composes phenylpyrroliques utiles en tant que medicaments, leur preparation et leur application
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
CA2017466A1 (en) 1989-06-02 1990-12-02 Michael C. Kiefer Bone calcification factor
CA2020729A1 (en) 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein
CA2064878A1 (en) 1989-08-21 1991-02-22 Hanne Bentz Bone-specific protein
CA2024629C (en) 1989-09-06 2001-07-24 Taiheiyo Cement Corporation Xenopus laevis bone morphogenic protein, dna encoding same and use thereof
DK0448704T3 (da) 1989-10-17 1999-04-06 Stryker Corp Osteogene anordninger
US5168050A (en) * 1990-05-24 1992-12-01 Genentech, Inc. Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion
AU8941791A (en) 1990-10-18 1992-05-20 Creative Biomolecules, Inc. Osteogenic protein
CA2094027C (en) 1990-10-18 2001-12-25 Hermann Oppermann Osteogenic peptides
EP0592562B1 (de) * 1991-06-25 1999-01-07 Genetics Institute, Inc. Bmp-9 zusammensetzungen
AU669127B2 (en) 1991-08-30 1996-05-30 Stryker Corporation Morphogen-induced modulation of inflammatory response
ES2253736T3 (es) 1991-08-30 2006-06-01 Curis, Inc. Tratamiento para prevenir la perdida y/o aumentar la masa osea en transtornos metabolicos del hueso.
CA2144514C (en) * 1992-09-16 2002-03-26 Thangavel Kuberasampath Morphogen-induced liver regeneration
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins

Also Published As

Publication number Publication date
US6287816B1 (en) 2001-09-11
EP1230930A2 (de) 2002-08-14
ATE223486T1 (de) 2002-09-15
AU709869B2 (en) 1999-09-09
US6034061A (en) 2000-03-07
EP0764208B1 (de) 2002-09-04
JPH10503927A (ja) 1998-04-14
WO1995033830A1 (en) 1995-12-14
EP0764208A1 (de) 1997-03-26
AU2817095A (en) 1996-01-04
KR100255417B1 (ko) 2000-05-01
EP1230930A3 (de) 2002-11-27
JP3706133B2 (ja) 2005-10-12
DE69528058T2 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
DE69528058D1 (de) Bmp-9 zusammensetzungen
ATE162223T1 (de) Osteoinduktive zusammensetzungen
CA2108770A1 (en) Bmp-9 compositions
DK0536186T3 (da) Knogle- og brusk-dannelsesfremkaldende proteiner
ATE265529T1 (de) Bmp-10 zusammensetzungen
DE60007079D1 (de) Methoden und zusammensetzungen zur heilung und reparatur von gelenkknorpeln
DE60137430D1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
FI962350A (fi) BPM-12, BMP-13 sekä niiden jännettä indusoivat koostumukset
DK1690874T3 (da) BMP-12, BMP-13 og sene-inducerende sammensætninger deraf
DE60043075D1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
DE69133338D1 (de) Bmp-5-derivate
DE60000501D1 (de) Verwendung von melanomhemmendem faktor zur reparatur von knorpelgewebe und knochen
ATE255920T1 (de) Methoden und zusammensetzungen zur heilung und reparatur von gelenkknorpeln
ATE195424T1 (de) Verfahren zur verbesserung der wundheilung und gewebeerneuerung
DE69331479T2 (de) Polyethylenglycol-Hirudin-Konjugate, deren Verfahren zur Herstellung und Verwendung für die Heilung von Thrombosen
DE69433055D1 (de) Zusammensetzung zum heilen von verletztem gewebe, verfahren für ihre herstellung und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee